All In Biotech

Drug Trial Radar · NCT01615796

Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses

A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.

Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Jun 4, 2012

Primary completion

Feb 21, 2014

Study completion Feb 21, 2014

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft tissue infections including isolates resistant to existing classes of antimicrobials.

Conditions

  • Infections, Respiratory Tract

Interventions

  • Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determinedDrug

    Subjects receive a single dose of GSK2140944

  • Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determinedDrug

    Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of pharmacokinetic (PK) parameters of GSK2140944 including area under the curve following single dose administration.Time frame: Part A up to 4 days
  2. Composite of PK parameters for GSK2140944 following single dose administrationTime frame: Part A up to 4 Days
  3. Composite of PK parameters for GSK2140944 including area under the curve following repeat dose administration.Time frame: Part B Days 4, 7, 10 and 14
  4. Composite of PK parameters for GSK2140944 following repeat dose administration.Time frame: Part B Days 4, 7, 10 and 14
  5. Composite of PK parameters for GSK2140944 following repeat dose administration including maximum concentration, area under the curve, accumulation ratio and clearance of parent drub.Time frame: Part B Days 4, 7, 10 and 14
  6. GSK2140944 safety parameters - adverse eventsTime frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days
  7. GSK2140944 safety parameters - telemetryTime frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days
  8. GSK2140944 safety parameters - absolute values and changes over time of hematology, clinical chemistry and urinalysisTime frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days
  9. GSK2140944 safety parameters - vital signs (blood pressure, heart rate, temperature)Time frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days
  10. GSK2140944 safety parameters - Electrocardiogram (ECG) measurementsTime frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.